HDAC6 and prostate neoplasm: These results corroborate our findings that the dual inhibition of PI3K and HDAC6 through LASSBio-2208 may be a better alternative for reducing the viability of prostate tumor cells, as it was more potent than the inhibition of only HDAC6/8.